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Recent critical publications on neurofeedback raise a conundrum: Does EEGneurofeedback (EEG-nf) work, and if so, how? In a series of papers, we reported that EEG-nf
seems to help the symptoms of ADHD, but for different reasons than most advocates would
expect—i.e., due to a placebo response (Thibault, Lifshitz, Birbaumer, & Raz, 2015; Thibault &
Raz, 2017). In this Guest Editorial, we address ethical considerations concerning prescribing
placebos and highlight how we can leverage prevailing brain-based beliefs about behavioral
disorders to better treat patients. We conclude that clinicians can apply EEG-nf to ADHD as a
form of clinical suggestion for patients with the time, finances, and inclination to pursue such a
treatment.	
  
In a therapeutic context, suggestion refers to communicable ideas, contextual cues, and
cultural rituals that can help modulate both voluntary actions and autonomic functions that
typically lie outside of our volitional control. Suggestions come in many flavors (e.g., hypnotic,
parental, or commercial). In this paper we focus on the kind of suggestion that uses ideas, cues,
and rituals drawn from neuro-technology and our culturally widespread trust in brain-based
explanatory models of human behavior—i.e., neurosuggestion. To enhance the involvement of
the patient and to make suggestion more effective, we can leverage culturally salient props, such
as a brain scanner, in a process we broadly term accessory-assisted healing.	
  

Why EEG-neurofeedback is neurosuggestion therapy	
  
EEG-nf for ADHD shows comparable benefits whether the feedback is genuine (from
one’s own brain signal of interest) or a sham (from an unrelated signal). To date, every relevant
double-blind sham-controlled study has reached this conclusion (Arnold et al., 2013;
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Lansbergen, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2011; Logemann,
Lansbergen, van Os, Bocker, & Kenemans, 2010; Perreau-Linck, Lessard, Lévesque, &
Beauregard, 2010; Schönenberg et al., 2017; Thibault & Raz, 2017; Van Dongen-Boomsma,
Vollebregt, Slaats-Willemse, & Buitelaar, 2013; Vollebregt, van Dongen-Boomsma, Buitelaar,
& Slaats-Willemse, 2014). In all but two of these studies, the treatment benefitted both groups
(Logemann et al., 2010; Vollebregt et al., 2014). A recent triple-blind registered randomized
controlled trials (RCT) with 118 participants diagnosed with ADHD found large effect sizes for
both true (d=1.0) and sham (d=1.5) neurofeedback groups (Schönenberg et al., 2017). Until
research demonstrates additional benefits from true neurofeedback that go above and beyond
placebo effects, the science suggests that EEG-nf, at least in its current incarnation, relies
exclusively on treatment mechanisms unrelated to watching one’s own brain activity (Thibault &
Raz, 2016). EEG-nf, in other words, is neurosuggestion.	
  

We already prescribe suggestion
Most clinicians have prescribed suggestion—but many don’t know it. The benefits of
SSRIs for depression, acupuncture for lower back pain, and knee surgery for osteoarthritis all
stem largely from the suggestion that these treatments will improve your health (i.e., from
placebo effects). In 2002, the psychologist Irving Kirsch obtained unpublished clinical trial data
under the Freedom of Information Act, and found that SSRIs barely outperformed placebos in
RCTs (Kirsch, Moore, Scoboria, & Nicholls, 2002). In the case of lower back pain, two RCTs
with a total of over 1,700 participants demonstrated comparable benefits between veridical
acupuncture and sham acupuncture, yet both outperformed a standard-of-care treatment (Cherkin
et al., 2009; Haake, Basler, & Endres, 2007; Harris, Lifshitz, & Raz, 2015). Likewise, a high-
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profile RCT showed that, even at a two-year follow-up, sham knee surgery decreased pain and
improved movement capacity on par with real surgery (Moseley et al., 2002). An expert panel
now strongly recommends against knee surgery for osteoarthritis due to potential complications
and the absence of benefits beyond placebo effects (Siemieniuk et al., 2017). In these situation,
clinicians often unknowingly prescribe placebos. Following the results from recent double-blind
studies, we can now add EEG-nf for ADHD to this list of placebo therapies that masquerade
under other biomedical labels.	
  

The case for suggestion in ADHD
In contrast to the abovementioned placebo therapies, psychostimulants typically reduce
ADHD symptoms more effectively than placebo, but come at a cost. Potential side-effects
include crying, staring, anxiety, sadness, nail biting, euphoria, and shyness (Konrad-Bindl,
Gresser, & Richartz, 2016). Due to growing concerns about long-term adverse side-effects, the
European Commission recently called for a two-year longitudinal study that is taking place at 27
sites (Inglis et al., 2016). Given the potential for harm, it is advantageous to consider drug-free
treatments with minimal side-effects to complement or replace psychostimulants. In this vein, a
pair of studies found that when children with ADHD were prescribed an “open-label” placebo,
they could cut their psychostimulant intake in half with negligible changes in behavior (Sandler
& Bodfish, 2008; Sandler, Glesne, & Bodfish, 2010). In lieu of deception, the researchers briefed
children with the following script:	
  

“This little capsule is a placebo. Placebos have been used a lot in treating people. It is
called ‘Dose Extender.’ As you can see, it is different from Adderall. Dose Extender is
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something new. It has no drug in it. I can promise you that it won’t hurt you at all. It has
no real side effects. But it may help you to help yourself. It may work well with your
Adderall, kind of like a booster to the dose of Adderall. That’s why it’s called a Dose
Extender. I won’t be surprised when I hear from you and your parents and your teachers
that you’re able to control your ADHD better.” (Sandler & Bodfish, 2008, p.106) 	
  

Full disclosure made little impact on the effectiveness of the placebo condition—i.e.,
administering placebos openly hardly detracted from the clinical benefit (Sandler et al, 2008).
Researchers have reproduced this finding in several conditions, including irritable bowel
syndrome, chronic pain, and depression (Kaptchuk et al., 2010; Kelley, Kaptchuk, Cusin, Lipkin,
& Fava, 2012; Schafer, Colloca, & Wager, 2015).	
  
Based on staunch faith in brain science, neurosuggestion may perhaps treat patients even
better than placebo pills. In particular, with EEG-nf for ADHD, the suggestion that physical
movement will contaminate the expensive brain recordings can lead participants to sit still and in
turn, this procedure provides an ulterior form of behavioral therapy. The additional psychosocial
cues surrounding EEG-nf, compared to those present when ingesting a pill, may help this
technique compete with standard pharmacotherapy (e.g., Fuchs, Birbaumer, Lutzenberger,
Gruzelier, & Kaiser, 2003). To further support this point scientifically and to the level of clinical
recommendation, more studies would need to directly compare EEG-nf with standard of care
treatment.	
  

Testing neurosuggestion in the clinic
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In our previous work, we explored how strong this type of suggestion could be. We found
that many participants believed that a crudely-built “brain scanner”—assembled from discarded
hair drying and medical equipment and placed in a cognitive neuroscience laboratory—could
read their minds (Ali, Lifshitz, & Raz, 2014). In subsequent iterations of this paradigm, we found
that a more realistic looking scanner could similarly alter people’s sense of agency and moral
attitudes (Olson, Landry, Appourchaux, & Raz, 2016; Olson, Strandberg, Hall, Johansson, &
Raz, 2017). In light of these findings, we decided to test the clinical applications of this
technique we term neurosuggestion.	
  

To pilot the idea, we used a real but decommissioned—in other words, sham—Magnetic
Resonance Imaging (MRI) scanner at the Montreal Neurological Institute as part of an openlabel procedure to treat nine children diagnosed with ADHD (Figure 1; Veissière, Olson, & Raz,
2017). We told the children that the “brain machine” was inactive, and that we would “use it as a
suggestion” that would “help their brain heal itself”. While in the defunct scanner, we gave the
children positive verbal suggestions to promote relaxation, focus, and confidence. At one- three-,
and six-week follow-ups, parents reported improvements in eight out of the nine participating
children. In qualitative interviews, two families reported near complete remission of symptoms,
and six reported improvements in areas such as confidence, self-control, and social skills. None
reported any side effects. In essence, this study provided neurofeedback-like treatment, but
instead of focusing on a specific physiological mechanism, we emphasized suggestion based
healing.
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Figure 1: Decommissioned Siemens 1.5T MRI used for the neurosuggestion procedure.

Should we prescribe EEG-nf for ADHD?
To answer this question, we need to consider a few issues. First, as a culture, we maintain
deep-set beliefs that the origin of behavioral disorders resides in the brain (Moncrieff, 2016;
Rose, 2003). Relying on this assumption, children and their families often actively seek a
diagnostic label, for example ADHD, in order to ascribe meaning to their behavior (Moncrieff,
2016; Moncrieff, Rapley, & Timimi, 2015). Second, even in our open-label neurosuggestion
experiment (Veissière et al., 2017), parents continued to ask what was “wrong” with their child’s
brain, despite having been extensively briefed regarding the inert nature of the MRI scanner. And
yet, this very belief system—that a brain disorder is the core reason for the symptoms—may
unintentionally act as a suggestion to further obfuscate the situation and exacerbate symptoms
through nocebo effects (Loftus & Fries, 1979). This type of thinking has been described as a
“looping effect”, where our beliefs and social norms affect the framing, course, and outcomes of
a disorder (Hacking, 1995). In other words, context and culture strongly modulate how patients
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attend to and construe their behavior, which in turn, alters their symptoms (Kirmayer, GomezCarrillo, & Veissière, 2017; Seth & Friston, 2016). Third, our experiments show that brain-based
folk explanations can lead to both nocebo and placebo effects. It seems that neurofeedback likely
summons its strength from this belief system, which offers a promising means to regulate
“faulty” brain patterns (Thibault & Raz, 2017). Thus, neurosuggestion, rather than the act of
regulating one’s own EEG waves, likely allows patients to break free from harmful looping
effects.	
  
In sum, under certain circumstances, clinicians could ethically and non-deceptively
prescribe EEG-nf as a form of neurosuggestion therapy. It wouldn’t be the first placebo
prescription—in the United States, one study reports that 45% of physicians use placebos in
clinical practice and 96% of them believe placebos can have therapeutic effects (Sherman &
Hickner, 2008); in Canada, an analysis of placebo use among physicians, and especially
psychiatrists, echoes similar sentiments (Raz et al., 2011). Moreover, a recent study describes
interviews with 1,000 parents and reports that most deem it acceptable for clinicians to
recommend placebo treatment for ADHD (Faria et al., 2017). With these realities in mind, EEGnf presents a reasonable alternative for patients experiencing adverse side-effects or simply
searching for a non-pharmacological treatment. Because EEG-nf requires time, money, and
energy, if clinicians decide to promote this technique, they ought to present it as one of several
options (e.g., exercise, cognitive training, behavioral therapy, and diet; Sonuga-Barke et al.,
2013). Thus, clinicians can certainly prescribe EEG-nf. We recommend they do so transparently
and with an eye for amplifying the psychosocial mechanisms of suggestion rather than grasping
at the elusive neural signatures many practitioners speciously assign as the cause of ADHD.	
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